hydroxychloroquine has been researched along with Kidney Failure, Chronic in 37 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hydroxychloroquine was administered as therapy for the hypercalcemia." | 5.27 | Hydroxychloroquine treatment of hypercalcemia in a patient with sarcoidosis undergoing hemodialysis. ( Barré, PE; Gascon-Barré, M; Goltzman, D; Meakins, JL, 1987) |
| "A female patient from the French Antilles developed renal failure due to pure chronic interstitial nephritis six months after the onset of systemic lupus erythematosus (SLE) for which she was taking hydroxychloroquine." | 3.68 | [Lupus, sicca syndrome and chronic interstitial nephritis. Apropos of a case]. ( Blanche, P; Sicard, D, 1992) |
| "001), and average oral dosage of >7." | 1.72 | Pneumocystis Jirovecii Pneumonia in Systemic Lupus Erythematosus: A Nationwide Cohort Study in Taiwan. ( Chang, YS; Chen, WS; Huang, YF; Lai, CC; Li, TH; Tsao, YP; Wang, WH, 2022) |
| "We identified incident ESRD patients age ≥18 years with SLE as a primary cause of ESRD between January 2006 and June 2013." | 1.72 | Prescribing Patterns of Hydroxychloroquine and Glucocorticoids Among Lupus Patients After New-Onset End-Stage Renal Disease. ( Broder, A; Costenbader, KH; Feldman, CH; Kim, M; Mowrey, WB; Valle, A; Yoshida, K, 2022) |
| "Hydroxychloroquine (HQ) has been used for the treatment of novel coronavirus disease (COVID-19) even though there is no clear evidence for its effectiveness yet." | 1.62 | Sudden Cardiac Death in Haemodialysis Patients under Hydroxychloroquine Treatment for COVID-19: A Report of Two Cases. ( Dincer, MT; Karaca, C; Murt, A, 2021) |
| "Hydroxychloroquine (HCQ) was used by 78." | 1.56 | Early impact of COVID-19 on transplant center practices and policies in the United States. ( Avery, RK; Boyarsky, BJ; Durand, CM; Garonzik-Wang, JM; Getsin, SN; Jackson, KR; Kernodle, AB; Massie, AB; Po-Yu Chiang, T; Segev, DL; Van Pilsum Rasmussen, SE; Werbel, WA, 2020) |
| "The fatality of novel coronavirus disease 2019 (COVID-19) is precipitously increased in patients with underlying comorbidities or elderly people." | 1.56 | Two distinct cases with COVID-19 in kidney transplant recipients. ( Han, S; Hyun, M; Jin, K; Kim, HA; Kim, Y; Kwon, O; Lee, JY; Paek, JH; Park, WY, 2020) |
| "Eight percent died and 5% developed acute respiratory distress syndrome (ARDS)." | 1.56 | A report from the Brescia Renal COVID Task Force on the clinical characteristics and short-term outcome of hemodialysis patients with SARS-CoV-2 infection. ( Affatato, S; Alberici, F; Boni, F; Bossini, N; Bove, S; Bracchi, M; Calcaterra, E; Camerini, C; Cortinovis, R; Costantino, EM; Delbarba, E; Econimo, L; Gaggia, P; Gaggiotti, M; Gallico, A; Guerini, A; Lucca, B; Maffei, C; Manenti, C; Movilli, E; Mucchetti, A; Pezzini, E; Piarulli, P; Pola, A; Possenti, S; Saccà, C; Scolari, F; Terlizzi, V; Valerio, F; Zappa, M; Zubani, R, 2020) |
| "The evolving pandemic of Coronavirus Disease 2019 has posed a substantial health risk worldwide." | 1.56 | A Patient with Cryoglobulinemic Membranoproliferative GN (MPGN) Who Survived COVID-19 Disease: Case Presentation and Current Data of COVID-19 Infection in Dialysis and Transplanted Patients in Greece. ( Argyraki, A; Boletis, I; Grigorakos, K; Lourida, P; Marinaki, S; Skalioti, C; Tsiakas, S, 2020) |
| "Hydroxychloroquine (HCQ) is an antimalarial drug with immunomodulatory effects used to treat systemic lupus erythematosus (SLE) and scleroderma." | 1.56 | Hydroxychloroquine and maintenance immunosuppression use in kidney transplant recipients: Analysis of linked US registry and claims data. ( Alhamad, T; Axelrod, D; Brennan, DC; Caliskan, Y; Chang, SH; Hess, GP; Kasiske, BL; Lam, NN; Lentine, KL; McAdams-DeMarco, M; Schnitzler, MA; Segev, DL; Xiao, H, 2020) |
| "SLE manifestations after ESRD may be underdiagnosed and undertreated, contributing to increased morbidity and mortality." | 1.56 | Systemic lupus Erythematosus activity and Hydroxychloroquine use before and after end-stage renal disease. ( Broder, A; Dobrowolski, C; Goilav, B; Londono Jimenez, A; Mowrey, WB; Salgado Guerrero, M; Wang, S, 2020) |
| "One objective in the treatment of systemic lupus erythematosus (SLE) disease activity is to reduce long-term rates of organ damage." | 1.48 | Comparison of Remission and Lupus Low Disease Activity State in Damage Prevention in a United States Systemic Lupus Erythematosus Cohort. ( Magder, LS; Petri, M, 2018) |
| "Hydroxychloroquine was the most frequently filled DMARD (13." | 1.46 | End-stage renal disease in patients with rheumatoid arthritis. ( Bethel, M; Brown, S; Carbone, L; Chen, CC; Nahman, NS; Paudyal, S; Rice, C; Skelton, M; Yang, FM, 2017) |
| "To determine dosing patterns and examine predictors of filled hydroxychloroquine (HCQ) prescriptions in patients with systemic lupus erythematosus (SLE) with end-stage renal disease (ESRD)." | 1.43 | Hydroxychloroquine in patients with systemic lupus erythematosus with end-stage renal disease. ( Bethel, M; Carbone, LD; Li, S; Machua, W; Nahman, NS; Oliver, AM; Yang, FM, 2016) |
| "Osseous metaplasia has recently been described in several cases of nephrogenic systemic fibrosis, sometimes in association with unusual clinical features such as painful hyperkeratotic spicules, palpable bony masses, and disease regression." | 1.36 | Osseous metaplasia late in the course of nephrogenic systemic fibrosis. ( Bayliss, SJ; Berk, DR; Lu, D; Miller, A; Scarlett, D; Wippold, FJ, 2010) |
| "Hydroxychloroquine was administered as therapy for the hypercalcemia." | 1.27 | Hydroxychloroquine treatment of hypercalcemia in a patient with sarcoidosis undergoing hemodialysis. ( Barré, PE; Gascon-Barré, M; Goltzman, D; Meakins, JL, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (5.41) | 18.7374 |
| 1990's | 2 (5.41) | 18.2507 |
| 2000's | 3 (8.11) | 29.6817 |
| 2010's | 5 (13.51) | 24.3611 |
| 2020's | 25 (67.57) | 2.80 |
| Authors | Studies |
|---|---|
| Mucke, J | 1 |
| Schneider, M | 2 |
| Parikh, SV | 1 |
| Almaani, S | 1 |
| Brodsky, S | 1 |
| Rovin, BH | 1 |
| Fanouriakis, A | 1 |
| Kostopoulou, M | 1 |
| Cheema, K | 1 |
| Anders, HJ | 1 |
| Aringer, M | 1 |
| Bajema, I | 1 |
| Boletis, J | 1 |
| Frangou, E | 1 |
| Houssiau, FA | 1 |
| Hollis, J | 1 |
| Karras, A | 1 |
| Marchiori, F | 1 |
| Marks, SD | 1 |
| Moroni, G | 1 |
| Mosca, M | 1 |
| Parodis, I | 1 |
| Praga, M | 2 |
| Smolen, JS | 1 |
| Tesar, V | 1 |
| Trachana, M | 1 |
| van Vollenhoven, RF | 1 |
| Voskuyl, AE | 1 |
| Teng, YKO | 1 |
| van Leew, B | 1 |
| Bertsias, G | 1 |
| Jayne, D | 1 |
| Boumpas, DT | 1 |
| Gandolfini, I | 1 |
| Delsante, M | 1 |
| Fiaccadori, E | 1 |
| Zaza, G | 1 |
| Manenti, L | 1 |
| Degli Antoni, A | 1 |
| Peruzzi, L | 1 |
| Riella, LV | 1 |
| Cravedi, P | 1 |
| Maggiore, U | 1 |
| Bartiromo, M | 1 |
| Borchi, B | 1 |
| Botta, A | 1 |
| Bagalà, A | 1 |
| Lugli, G | 1 |
| Tilli, M | 1 |
| Cavallo, A | 1 |
| Xhaferi, B | 1 |
| Cutruzzulà, R | 1 |
| Vaglio, A | 1 |
| Bresci, S | 1 |
| Larti, A | 1 |
| Bartoloni, A | 1 |
| Cirami, C | 1 |
| Boyarsky, BJ | 1 |
| Po-Yu Chiang, T | 1 |
| Werbel, WA | 1 |
| Durand, CM | 1 |
| Avery, RK | 1 |
| Getsin, SN | 1 |
| Jackson, KR | 1 |
| Kernodle, AB | 1 |
| Van Pilsum Rasmussen, SE | 1 |
| Massie, AB | 1 |
| Segev, DL | 2 |
| Garonzik-Wang, JM | 1 |
| Hsu, JJ | 1 |
| Gaynor, P | 1 |
| Kamath, M | 1 |
| Fan, A | 1 |
| Al-Saffar, F | 1 |
| Cruz, D | 1 |
| Nsair, A | 1 |
| Fontana, F | 1 |
| Alfano, G | 1 |
| Mori, G | 1 |
| Amurri, A | 1 |
| Tei, L | 1 |
| Ballestri, M | 1 |
| Leonelli, M | 1 |
| Facchini, F | 1 |
| Damiano, F | 1 |
| Magistroni, R | 1 |
| Cappelli, G | 1 |
| Kim, Y | 1 |
| Kwon, O | 1 |
| Paek, JH | 1 |
| Park, WY | 1 |
| Jin, K | 1 |
| Hyun, M | 1 |
| Lee, JY | 1 |
| Kim, HA | 1 |
| Han, S | 1 |
| Alberici, F | 1 |
| Delbarba, E | 1 |
| Manenti, C | 1 |
| Econimo, L | 1 |
| Valerio, F | 1 |
| Pola, A | 1 |
| Maffei, C | 1 |
| Possenti, S | 1 |
| Lucca, B | 1 |
| Cortinovis, R | 1 |
| Terlizzi, V | 1 |
| Zappa, M | 1 |
| Saccà, C | 1 |
| Pezzini, E | 1 |
| Calcaterra, E | 1 |
| Piarulli, P | 1 |
| Guerini, A | 1 |
| Boni, F | 1 |
| Gallico, A | 1 |
| Mucchetti, A | 1 |
| Affatato, S | 1 |
| Bove, S | 1 |
| Bracchi, M | 1 |
| Costantino, EM | 1 |
| Zubani, R | 1 |
| Camerini, C | 1 |
| Gaggia, P | 1 |
| Movilli, E | 1 |
| Bossini, N | 1 |
| Gaggiotti, M | 1 |
| Scolari, F | 1 |
| Kuroki, Y | 1 |
| Hiyama, K | 1 |
| Minami, J | 1 |
| Takeuchi, M | 1 |
| Shojima, M | 1 |
| Matsueda, S | 1 |
| Nagae, H | 1 |
| Nakano, T | 1 |
| Dirim, AB | 1 |
| Demir, E | 1 |
| Ucar, AR | 1 |
| Garayeva, N | 1 |
| Safak, S | 1 |
| Oto, OA | 1 |
| Yazici, H | 1 |
| Alibeyoglu, AM | 1 |
| Orhun, G | 1 |
| Cagatay, AA | 1 |
| Turkmen, A | 1 |
| Mehta, SA | 1 |
| Leonard, J | 1 |
| Labella, P | 1 |
| Cartiera, K | 1 |
| Soomro, I | 1 |
| Neumann, H | 1 |
| Montgomery, RA | 1 |
| Ali, NM | 1 |
| Gajurel, K | 1 |
| Marinaki, S | 1 |
| Tsiakas, S | 1 |
| Skalioti, C | 1 |
| Lourida, P | 1 |
| Argyraki, A | 1 |
| Grigorakos, K | 1 |
| Boletis, I | 1 |
| Giaime, P | 1 |
| Guenoun, M | 1 |
| Pedinielli, N | 1 |
| Narbonne, H | 1 |
| Bergounioux, JP | 1 |
| Solas, C | 1 |
| Guilhaumou, R | 1 |
| Sampol, J | 1 |
| Ollier, J | 1 |
| Sichez, H | 1 |
| Serveaux, M | 1 |
| Brunner, F | 1 |
| Bataille, S | 1 |
| Sobol, I | 1 |
| Yuzefpolskaya, M | 1 |
| Roth, Z | 1 |
| Colombo, PC | 1 |
| Horn, E | 1 |
| Takeda, K | 1 |
| Sayer, G | 1 |
| Uriel, N | 1 |
| Naka, Y | 1 |
| Murt, A | 2 |
| Dincer, MT | 2 |
| Karaca, C | 2 |
| Lentine, KL | 1 |
| Lam, NN | 1 |
| Caliskan, Y | 1 |
| Alhamad, T | 1 |
| Xiao, H | 1 |
| Schnitzler, MA | 1 |
| Chang, SH | 1 |
| Axelrod, D | 1 |
| McAdams-DeMarco, M | 1 |
| Kasiske, BL | 1 |
| Hess, GP | 1 |
| Brennan, DC | 1 |
| Salgado Guerrero, M | 1 |
| Londono Jimenez, A | 1 |
| Dobrowolski, C | 1 |
| Mowrey, WB | 2 |
| Goilav, B | 1 |
| Wang, S | 1 |
| Broder, A | 2 |
| Trujillo, H | 1 |
| Fernández-Ruiz, M | 1 |
| Gutiérrez, E | 1 |
| Sevillano, Á | 1 |
| Caravaca-Fontán, F | 1 |
| Morales, E | 1 |
| López-Medrano, F | 1 |
| Aguado, JM | 1 |
| Andrés, A | 1 |
| Wang, WH | 1 |
| Lai, CC | 1 |
| Huang, YF | 1 |
| Li, TH | 1 |
| Tsao, YP | 1 |
| Chen, WS | 1 |
| Chang, YS | 1 |
| Ahmed, W | 1 |
| Al Obaidli, AAK | 1 |
| Joseph, P | 1 |
| Smith, ER | 1 |
| Khan, AA | 1 |
| Anwar, S | 1 |
| Chandrasekar, T | 1 |
| Al Madani, AK | 1 |
| Dastoor, HD | 1 |
| Zahid, I | 1 |
| Costales, FA | 1 |
| Boobes, YAR | 1 |
| Al Kindi, F | 1 |
| Issa, SEK | 1 |
| Hassan, MH | 1 |
| George, A | 1 |
| Holt, SG | 1 |
| Valle, A | 1 |
| Kim, M | 1 |
| Feldman, CH | 1 |
| Yoshida, K | 1 |
| Costenbader, KH | 1 |
| Petri, M | 1 |
| Magder, LS | 1 |
| Auguste, BL | 1 |
| Avila-Casado, C | 1 |
| Bargman, JM | 1 |
| Bethel, M | 2 |
| Yang, FM | 2 |
| Li, S | 1 |
| Nahman, NS | 2 |
| Oliver, AM | 1 |
| Machua, W | 1 |
| Carbone, LD | 1 |
| Paudyal, S | 1 |
| Rice, C | 1 |
| Chen, CC | 1 |
| Skelton, M | 1 |
| Brown, S | 1 |
| Carbone, L | 1 |
| Tarwater, K | 1 |
| Misra, S | 1 |
| Misra, M | 1 |
| Berk, DR | 1 |
| Miller, A | 1 |
| Scarlett, D | 1 |
| Wippold, FJ | 1 |
| Bayliss, SJ | 1 |
| Lu, D | 1 |
| Shahnaz, S | 1 |
| Choksi, MT | 1 |
| Tan, IJ | 1 |
| Sisó, A | 1 |
| Ramos-Casals, M | 1 |
| Bové, A | 1 |
| Brito-Zerón, P | 1 |
| Soria, N | 1 |
| Muñoz, S | 1 |
| Testi, A | 1 |
| Plaza, J | 1 |
| Sentís, J | 1 |
| Coca, A | 1 |
| Harber, LC | 1 |
| Bickers, DR | 1 |
| Sinha, RN | 1 |
| Fraser, WD | 1 |
| Casson, IF | 1 |
| Blanche, P | 1 |
| Sicard, D | 1 |
| Barré, PE | 1 |
| Gascon-Barré, M | 1 |
| Meakins, JL | 1 |
| Goltzman, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Minimizing Glucocorticoid Administration in Patients With Proliferative Lupus Nephritis During the Induction of Remission Period-EUROLUPUS vs. RITUXILUP Regimen: A Randomized Study[NCT05207358] | Phase 4 | 30 participants (Anticipated) | Interventional | 2022-03-02 | Recruiting | ||
| Effectiveness of Mycophenolate Mofetil Combined With Tacrolimus for Steroid Tapering in Systemic Lupus Erythematosus: A Prospective, Random Control, Open-label, Single Center Clinical Trial[NCT05916781] | Phase 4 | 220 participants (Anticipated) | Interventional | 2023-07-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for hydroxychloroquine and Kidney Failure, Chronic
| Article | Year |
|---|---|
Update on Lupus Nephritis: Core Curriculum 2020.
Topics: Adaptive Immunity; Adrenal Cortex Hormones; Age Distribution; Autoantibodies; Autoimmunity; Biopsy; | 2020 |
Invasive pulmonary aspergillosis associated with COVID-19 in a kidney transplant recipient.
Topics: Acute Kidney Injury; Administration, Inhalation; Amphotericin B; Anti-Bacterial Agents; Antibodies, | 2021 |
35 other studies available for hydroxychloroquine and Kidney Failure, Chronic
| Article | Year |
|---|---|
[Lupus nephritis].
Topics: Humans; Hydroxychloroquine; Immunosuppressive Agents; Kidney; Kidney Failure, Chronic; Lupus Erythem | 2023 |
2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis.
Topics: Antirheumatic Agents; Azathioprine; Calcineurin Inhibitors; Drug Therapy, Combination; Europe; Glome | 2020 |
COVID-19 in kidney transplant recipients.
Topics: Aged; Betacoronavirus; Cobicistat; Colchicine; Coronavirus Infections; COVID-19; Cytokines; Darunavi | 2020 |
Threatening drug-drug interaction in a kidney transplant patient with coronavirus disease 2019 (COVID-19).
Topics: Adult; Antiviral Agents; Betacoronavirus; C-Reactive Protein; Ciliopathies; Cobicistat; Common Cold; | 2020 |
Early impact of COVID-19 on transplant center practices and policies in the United States.
Topics: Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Betacoronavirus; Clinical Labor | 2020 |
COVID-19 in a high-risk dual heart and kidney transplant recipient.
Topics: Adenosine Monophosphate; Adult; Alanine; Betacoronavirus; Cardiomyopathy, Dilated; Coronavirus Infec | 2020 |
COVID-19 pneumonia in a kidney transplant recipient successfully treated with tocilizumab and hydroxychloroquine.
Topics: Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Comorbidity; Coronavirus Infec | 2020 |
Two distinct cases with COVID-19 in kidney transplant recipients.
Topics: Adult; Antiviral Agents; Azithromycin; Betacoronavirus; Calcineurin Inhibitors; Coronavirus Infectio | 2020 |
A report from the Brescia Renal COVID Task Force on the clinical characteristics and short-term outcome of hemodialysis patients with SARS-CoV-2 infection.
Topics: Aged; Aged, 80 and over; Antimalarials; Antiviral Agents; Coronavirus Infections; COVID-19; Female; | 2020 |
The first case of COVID-19 pneumonia in a hemodialysis patient in Japan.
Topics: Aged; Anti-Infective Agents; Anticoagulants; Combined Modality Therapy; Comorbidity; Coronavirus Inf | 2020 |
Fatal SARS-CoV-2 infection in a renal transplant recipient.
Topics: Antiviral Agents; Azithromycin; Betacoronavirus; Clinical Deterioration; Coronavirus Infections; COV | 2020 |
Outpatient management of kidney transplant recipients with suspected COVID-19-Single-center experience during the New York City surge.
Topics: Acute Kidney Injury; Ambulatory Care; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Azit | 2020 |
Persistently positive severe acute respiratory syndrome coronavirus 2 (SARS-COV2) nasopharyngeal PCR in a kidney transplant recipient.
Topics: Adult; COVID-19; Female; Glomerulosclerosis, Focal Segmental; Humans; Hydroxychloroquine; Immunocomp | 2020 |
A Patient with Cryoglobulinemic Membranoproliferative GN (MPGN) Who Survived COVID-19 Disease: Case Presentation and Current Data of COVID-19 Infection in Dialysis and Transplanted Patients in Greece.
Topics: Anti-Bacterial Agents; Azithromycin; Betacoronavirus; Ceftriaxone; Coronavirus Infections; COVID-19; | 2020 |
Hydroxychloroquine and azithromycin tolerance in haemodialysis patients during COVID-19 infection.
Topics: Aged; Anti-Bacterial Agents; Antimalarials; Azithromycin; Betacoronavirus; Comorbidity; Coronavirus | 2020 |
Characteristics and Outcomes of Patients With a Left Ventricular Assist Device With Coronavirus Disease-19.
Topics: Adult; Aged; Anticoagulants; Betacoronavirus; Coronavirus Infections; COVID-19; Diabetes Mellitus; F | 2020 |
Sudden Cardiac Death in Haemodialysis Patients under Hydroxychloroquine Treatment for COVID-19: A Report of Two Cases.
Topics: Aged; Aged, 80 and over; Azithromycin; COVID-19; COVID-19 Drug Treatment; Death, Sudden, Cardiac; Dr | 2021 |
Hydroxychloroquine and maintenance immunosuppression use in kidney transplant recipients: Analysis of linked US registry and claims data.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Drug Therapy, Combination; Female; Graft Rejection; Graf | 2020 |
Systemic lupus Erythematosus activity and Hydroxychloroquine use before and after end-stage renal disease.
Topics: Adult; Autoantibodies; Biomarkers; Complement System Proteins; Disease Progression; DNA; Enzyme Inhi | 2020 |
Pneumocystis Jirovecii Pneumonia in Systemic Lupus Erythematosus: A Nationwide Cohort Study in Taiwan.
Topics: Cohort Studies; Cyclophosphamide; Humans; Hydroxychloroquine; Kidney Failure, Chronic; Lupus Erythem | 2022 |
Shall We Use Hydroxychloroquine in Hemodialysis Patients?
Topics: Humans; Hydroxychloroquine; Kidney Failure, Chronic; Renal Dialysis | 2022 |
Outcomes of patients with end stage kidney disease on dialysis with COVID-19 in Abu Dhabi, United Arab Emirates; from PCR to antibody.
Topics: Adrenal Cortex Hormones; Adult; Antibodies, Viral; Antiviral Agents; Asymptomatic Infections; Commun | 2021 |
Prescribing Patterns of Hydroxychloroquine and Glucocorticoids Among Lupus Patients After New-Onset End-Stage Renal Disease.
Topics: Adolescent; Aged; Antirheumatic Agents; Glucocorticoids; Humans; Hydroxychloroquine; Kidney Failure, | 2022 |
Comparison of Remission and Lupus Low Disease Activity State in Damage Prevention in a United States Systemic Lupus Erythematosus Cohort.
Topics: Adult; Antirheumatic Agents; Cardiomyopathies; Cataract; Cohort Studies; Diabetes Mellitus; Disease | 2018 |
Use of vitamin D drops leading to kidney failure in a 54-year-old man.
Topics: Creatinine; Directive Counseling; Enzyme Inhibitors; Humans; Hydroxychloroquine; Hypercalcemia; Kidn | 2019 |
Hydroxychloroquine in patients with systemic lupus erythematosus with end-stage renal disease.
Topics: Adult; Aged; Drug Prescriptions; Female; Humans; Hydroxychloroquine; Kidney Failure, Chronic; Lupus | 2016 |
End-stage renal disease in patients with rheumatoid arthritis.
Topics: Adalimumab; Adolescent; Adult; Amyloidosis; Antirheumatic Agents; Arthritis, Rheumatoid; Biological | 2017 |
Type I (sporadic) porphyria cutanea tarda in a hemodialysis patient: a case report.
Topics: Enzyme Inhibitors; Female; Hepatitis C; Humans; Hydroxychloroquine; Kidney Failure, Chronic; Middle | 2008 |
Osseous metaplasia late in the course of nephrogenic systemic fibrosis.
Topics: Adult; Analgesics; Calcinosis; Disease Progression; Female; gamma-Aminobutyric Acid; Humans; Hydroxy | 2010 |
Bilateral cytomegalovirus retinitis in a patient with systemic lupus erythematosus and end-stage renal disease.
Topics: Adult; Antirheumatic Agents; Azathioprine; Cytomegalovirus Retinitis; Female; HIV Seronegativity; Hu | 2003 |
Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival.
Topics: Adolescent; Adult; Aged; Antimalarials; Biopsy; Child; Chloroquine; Disease Progression; Female; Fol | 2008 |
Porphyria and pseudoporphyria.
Topics: Alcoholism; Bloodletting; Female; Furosemide; Humans; Hydroxychloroquine; Kidney Failure, Chronic; M | 1984 |
Long-term management of hypercalcaemia in chronically active sarcoidosis.
Topics: Adult; Chronic Disease; Diphosphonates; Drug Therapy, Combination; Fatal Outcome; Female; Humans; Hy | 1997 |
[Lupus, sicca syndrome and chronic interstitial nephritis. Apropos of a case].
Topics: Adult; Female; Humans; Hydroxychloroquine; Kidney Failure, Chronic; Lupus Erythematosus, Systemic; N | 1992 |
Hydroxychloroquine treatment of hypercalcemia in a patient with sarcoidosis undergoing hemodialysis.
Topics: Female; Humans; Hydroxychloroquine; Hydroxycholecalciferols; Hypercalcemia; Kidney Failure, Chronic; | 1987 |